Last reviewed · How we verify
HYD
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and cough suppression.
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and cough suppression. Used for Moderate to moderately severe pain, Cough suppression.
At a glance
| Generic name | HYD |
|---|---|
| Sponsor | Purdue Pharma LP |
| Drug class | Opioid analgesic |
| Target | Mu opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Hydrocodone activates mu opioid receptors throughout the brain and spinal cord, reducing the perception of pain and suppressing cough reflex signals. It is a semi-synthetic opioid derived from codeine and is typically formulated in combination with acetaminophen or ibuprofen for enhanced analgesic effect.
Approved indications
- Moderate to moderately severe pain
- Cough suppression
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Respiratory depression
- Dependence/addiction risk
Key clinical trials
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (PHASE3)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera (PHASE3)
- Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (PHASE2)
- Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire (PHASE4)
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HYD CI brief — competitive landscape report
- HYD updates RSS · CI watch RSS
- Purdue Pharma LP portfolio CI